Lixte Biotechnology Holdings, Inc. - LIXT STOCK NEWS

Lixte Biotechnology Holdings, Inc. announced recognition for Julio Pimentel, a doctoral student, for his research on LB-100 in triple negative breast cancer (TNBC). Pimentel was awarded the National Latino Leader Award and a scholarship to present his findings at a conference in October 2021. His research showed that LB-100 effectively inhibits TNBC cells and enhances the effectiveness of standard chemotherapy drugs like paclitaxel and cisplatin. Lixte's CEO highlighted the potential of LB-100 as a novel therapeutic approach for TNBC, which represents 15-20% of breast cancer cases in the U.S.

Lixte Biotechnology Holdings (Nasdaq: LIXT) is set to present at the MoneyShow July Virtual Expo from July 13-15, 2021. The event is accessible to the public and will feature a presentation by CEO John S. Kovach, M.D., outlining the Phase 1b/2 clinical trial for the lead compound LB-100, targeting extensive stage small cell lung cancer. This innovative trial is conducted in partnership with the City of Hope. Lixte is committed to developing effective cancer therapies and has achieved promising results with its PP2A inhibitor.

On June 2, 2021, Lixte Biotechnology Holdings announced the enrollment of the first patient in a Phase 1b clinical trial for LB-100, a PP2A inhibitor, in combination with chemotherapy for extensive stage small cell lung cancer (ED-SCLC). The trial, conducted at City of Hope, aims to assess the therapeutic benefit of LB-100 alongside carboplatin, etoposide, and atezolizumab. Preclinical data suggests that LB-100 enhances chemotherapy effectiveness in animal models. Approximately 30,000 new cases of small cell lung cancer are diagnosed annually in the U.S., highlighting the urgent need for effective treatments.

Lixte Biotechnology Holdings, Inc. has appointed Regina Brown, CPA, as an independent director and audit committee chair. Her extensive experience in public accounting, compliance, and taxation is seen as a valuable asset as the company expands. Brown has over 30 years of experience working with a diverse clientele, including large corporations and those with international operations. This appointment is expected to enhance Lixte's governance and oversight.

Lixte Biotechnology Holdings (Nasdaq: LIXT) announced participation in the Sidoti & Company LLC Virtual Microcap Conference on May 19-20, 2021. CEO John S. Kovach will present on May 20 at 12:15 p.m. ET, discussing the lead drug candidate LB-100, which enhances the efficacy of various anticancer treatments. Lixte's pipeline includes studies for four aggressive cancers, targeting a market exceeding $5 billion. The company aims to leverage its unique IP and lack of clinical competition for LB-100 to capture significant market share.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced participation in the virtual Benzinga Global Small Cap Conference on May 13-14, 2021. CEO John S. Kovach highlighted the potential of their lead drug candidate, LB-100, which targets aggressive cancers like myelodysplastic syndromes and glioblastoma. With a market exceeding $5 billion, Lixte aims to improve cancer treatment through its novel approach, having demonstrated positive preclinical results. The company's pipeline includes three clinical studies and one pharmacology study focused on LB-100.

Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced on April 13, 2021, the appointment of Gil N Schwartzberg to its Board of Directors following the resignation of Winson Ho. Dr. John S. Kovach, CEO, expressed confidence in Schwartzberg's contributions, noting his experience in guiding the company since its inception. Schwartzberg, former Chairman and CEO of the City of Hope National Medical Center, brings extensive expertise in cancer treatment and research. Lixte continues its focus on developing innovative cancer therapies, notably its lead compound, LB-100.

Lixte Biotechnology Holdings presents promising data on its lead drug candidate, LB-100, which has shown to enhance anti-tumor activity in over 40 preclinical studies without increasing toxicity. The company will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021, with CEO John S. Kovach discussing ongoing studies and clinical trials focused on cancers such as myelodysplastic syndrome and glioblastoma. Notably, LB-100 is a first-in-class agent with no known competitors currently in clinical trials.

Lixte Biotechnology Holdings, a clinical-stage drug discovery company, will participate in the 33rd Annual Roth Conference from March 15-17, 2021. CEO John S. Kovach will present their lead compound, LB-100, a first-in-class protein phosphatase inhibitor aimed at enhancing cancer treatments. Currently, LB-100 is being tested in various phases for several cancers, including Myelodysplastic Syndromes and Advanced Soft Tissue Sarcoma. Notably, LB-100 demonstrates potential without increasing toxicity, and there are currently no direct competitors in the market.